Stroke News and Research

RSS

A stroke is a medical emergency. Strokes happen when blood flow to your brain stops. Within minutes, brain cells begin to die. There are two kinds of stroke. The more common kind, called ischemic stroke, is caused by a blood clot that blocks or plugs a blood vessel in the brain. The other kind, called hemorrhagic stroke, is caused by a blood vessel that breaks and bleeds into the brain. "Mini-strokes" or transient ischemic attacks (TIAs), occur when the blood supply to the brain is briefly interrupted.

Drugs for prevention of breast cancer

According to an international panel of cancer experts, women at high risk of developing breast cancer should be given preventative drugs. The experts write in the Lancet Oncology adding, drugs such as tamoxifen could reduce the chances of developing breast cancer. They suggest that this would be something similar to prescribing statins to patients at risk of heart disease. But tamoxifen has been linked with womb cancer, blood clots and stroke.

28 Mar 2011

IMRIS sells IMRISNV to University of Utah Hospital

IMRIS Inc. today announced the sale of IMRISNV to University of Utah Hospital in Salt Lake City, Utah.

28 Mar 2011

Pathway Medical initiates enrollment in JETSTREAM G3 Calcium Study in peripheral artery disease

Pathway Medical Technologies, Inc., an innovator of endovascular treatments for peripheral vascular disease (PVD), today announced enrollment of the first patient in the company's JETSTREAM G3 Calcium Study, a prospective, single-arm, multi-center registry to evaluate the treatment effects of the JETSTREAM G3 System in patients with moderate to severely calcified peripheral artery disease.

28 Mar 2011

Study establishes strong link between nicotine and diabetes complications

Scientists today reported the first strong evidence implicating nicotine as the main culprit responsible for persistently elevated blood sugar levels - and the resulting increased risk of serious health complications - in people who have diabetes and smoke.

28 Mar 2011

Genentech's Lucentis Phase III trials in DME meets primary endpoints

Genentech, a member of the Roche Group, announced today that the second of two Phase III trials evaluating Lucentis in patients with diabetic macular edema met its primary endpoint.

28 Mar 2011

Study identifies unique adult animal stem cells that can turn into neurons

A group of scientists at Marshall University is conducting research that may someday lead to new treatments for repair of the central nervous system.

25 Mar 2011

Study finds increased risk of VTE during first year of combination oral contraceptive usage

Bayer HealthCare Pharmaceuticals Inc. today announced that interim results from a large, prospective, observational cohort safety study offer insights into the increased risk of venous thromboembolism (VTE), or blood clots, which is a well-established risk in women who use combination oral contraceptives (COCs), also known as "the Pill".

25 Mar 2011

New studies demonstrate advantages of Masimo noninvasive and continuous measurements in ICUs

Masimo announced today that three new studies presented at the International Symposium of Intensive Care and Emergency Medicine (ISICEM) Annual Meeting in Brussels, Belgium, demonstrate the accuracy, reliability, and clinical impact of Masimo noninvasive and continuous measurements—noninvasive hemoglobin (SpHb®), Pleth Variability Index (PVI®), and Perfusion Index (PI)—in Intensive Care Unit (ICU) patients.

25 Mar 2011

New Pediatric Physical Medicine and Rehabilitation Service at NewYork-Presbyterian Hospital

NewYork-Presbyterian Hospital has established a Pediatric Physical Medicine and Rehabilitation Service, led by Dr. Heakyung Kim. In this role, Dr. Kim will provide specialized care for children with neuromuscular disorders and other special needs at the Hospital's two major centers for pediatric care: Morgan Stanley Children's Hospital at NewYork-Presbyterian Hospital/Columbia University Medical Center and the Komansky Center for Children's Health at NewYork-Presbyterian Hospital/Weill Cornell Medical Center.

25 Mar 2011

Merck to return rights for betrixaban to Portola

Portola Pharmaceuticals and Merck, known as MSD outside the United States and Canada, today announced that Merck plans to return to Portola all rights for betrixaban, an investigational oral Factor Xa inhibitor anticoagulant being evaluated for the prevention of stroke in patients with atrial fibrillation (SPAF). This decision was made following a review of Merck's investigational portfolio.

25 Mar 2011

Osteoporosis study: Protelos have significant bone-forming activity than bisphosphonates

Protelos has significantly greater bone-forming activity than the commonly prescribed bisphosphonate, alendronate, according to results of the largest-ever biopsy study in post-menopausal women presented today at the European Congress on Osteoporosis and Osteoarthritis in Valencia.

25 Mar 2011

Non-invasive brain stimulation improves swallowing ability among stroke survivors

Stroke patients who received electrical brain stimulation coupled with swallowing exercises showed greater improvement in swallowing ability than patients who did not receive this stimulation, according to a pilot study reported in Stroke: Journal of the American Heart Association.

25 Mar 2011

First AngelMed Guardian cardiac monitor system implanted in patient at Jersey Shore

Today at Jersey Shore University Medical Center, 66-year-old heart attack survivor Charles Theodora from Ocean Township became the first NY/NJ Metropolitan resident to be implanted with the experimental AngelMed Guardian cardiac monitor and alert system device that could alert him if a heart attack is imminent.

25 Mar 2011

Dabigatran etexilate is less costly, more effective for stroke treatment in patients with AF

A new economic analysis, published online in Thrombosis and Haemostasis, suggested that Boehringer Ingelheim's novel oral direct thrombin inhibitor dabigatran etexilate is cost-effective compared to current treatment options, particularly in real-world clinical practice.

25 Mar 2011

Stemedica begins allogeneic mesenchymal stem cell Phase I/II trial in patients with ischemic stroke

Stemedica Cell Technologies, Inc., a leader in adult allogeneic stem cell manufacturing, research and development, announced today that its specially formulated ischemic adult allogeneic mesenchymal stem cells have been successfully used to treat the first patient in an ischemic stroke study conducted at the University of California, San Diego.

25 Mar 2011

UC Berkeley, UCSF partner to help develop neural prostheses for brain repair

Neuroscientists and engineers at UCSF and UC Berkeley have joined forces to help pioneer a new frontier of brain repair - the development of devices that would allow patients with such conditions as stroke, spinal cord injury, traumatic brain injury and Lou Gehrig's disease to control prosthetics through thoughts alone.

25 Mar 2011

Study finds risk of heart attack among patients with TIA

Patients who have suffered a "mini stroke" are at twice the risk of heart attack than the general population, according to research reported in Stroke: Journal of the American Heart Association.

25 Mar 2011

USPTO issues Notice of Allowance to AlphaRx ARX8203 pain product candidate

AlphaRx Inc. has received a Notice of Allowance from the United States Patent and Trademark Office for its lead pain product candidate code named ARX8203, a potentially safer drug intended for pain treatment.

25 Mar 2011

Quantum dots allow stem cell therapy monitoring for brain injury

A new technique using "quantum dots" produced through nanotechnology is a promising approach to monitoring the effects of stem cell therapies for stroke and other types of brain damage, reports the April issue of Neurosurgery, official journal of the Congress of Neurological Surgeons.

25 Mar 2011

Mercury in fish may not increase heart disease risk: Study

According to a new study Americans' level of exposure to mercury from sources such as fish is not associated with a higher risk of heart disease, stroke or other cardiovascular disease. This is in spite of the repeated proofs of neurological deficits in children and unborn babies due to mercury exposure.

24 Mar 2011

Stroke News and Research

Further Reading

Drugs for prevention of breast cancer

IMRIS sells IMRISNV to University of Utah Hospital

Pathway Medical initiates enrollment in JETSTREAM G3 Calcium Study in peripheral artery disease

Study establishes strong link between nicotine and diabetes complications

Genentech's Lucentis Phase III trials in DME meets primary endpoints

Study identifies unique adult animal stem cells that can turn into neurons

Study finds increased risk of VTE during first year of combination oral contraceptive usage

New studies demonstrate advantages of Masimo noninvasive and continuous measurements in ICUs

New Pediatric Physical Medicine and Rehabilitation Service at NewYork-Presbyterian Hospital

Merck to return rights for betrixaban to Portola

Osteoporosis study: Protelos have significant bone-forming activity than bisphosphonates

Non-invasive brain stimulation improves swallowing ability among stroke survivors

First AngelMed Guardian cardiac monitor system implanted in patient at Jersey Shore

Dabigatran etexilate is less costly, more effective for stroke treatment in patients with AF

Stemedica begins allogeneic mesenchymal stem cell Phase I/II trial in patients with ischemic stroke

UC Berkeley, UCSF partner to help develop neural prostheses for brain repair

Study finds risk of heart attack among patients with TIA

USPTO issues Notice of Allowance to AlphaRx ARX8203 pain product candidate

Quantum dots allow stem cell therapy monitoring for brain injury

Mercury in fish may not increase heart disease risk: Study

Discover how SciY empowers scientists

Why use light scattering to analyze proteins and viral vectors?

Changing the landscape of R&D to build clinical success from the ground up

Latest News